The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients

Results from the PROFILES registry

P.A.J. Vissers, F. Mols, M.S.Y. Thong, F. Pouwer, G. Vreugdenhil, L.V. van de Poll-Franse

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Purpose
This study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancer patients with diabetes less often receive chemotherapy.
Methods
Data from a cross-sectional study among CRC patients (2–11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20).
Results
Two hundred eighteen CRC patients with diabetes were matched on age and sex to 975 CRC patients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRC patients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95 % confidence interval (CI) 1.00–1.94), tingling toes or feet (OR = 1.47; 95 % CI 1.04–2.07), numbness in toes or feet (OR = 1.83; 95 % CI 1.28–2.62), and erection problems among men (OR = 1.83; 95 % CI 1.11–3.03) as compared to CRC patients without diabetes. No differences in cancer treatment were found between CRC patients with and without diabetes.
Conclusion
CRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancer patients with diabetes compared to those without.
Implications for Cancer Survivors
Up to 39 % of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes.
Keywords: Colorectal cancer, Diabetes, Neuropathic symptoms, Treatment, PROFILES, Eindhoven Cancer Registry
Original languageEnglish
Pages (from-to)523-531
JournalJournal of Cancer Survivorship
Volume9
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

Survival Rate
Neoplasms
Odds Ratio
Confidence Intervals
Logistic Models
Hypesthesia
Peripheral Nervous System Diseases
Survivors
Cross-Sectional Studies
Organizations

Cite this

@article{4bbdba7e610541e99862afd382ab3650,
title = "The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: Results from the PROFILES registry",
abstract = "PurposeThis study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancer patients with diabetes less often receive chemotherapy.MethodsData from a cross-sectional study among CRC patients (2–11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20).ResultsTwo hundred eighteen CRC patients with diabetes were matched on age and sex to 975 CRC patients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRC patients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95 {\%} confidence interval (CI) 1.00–1.94), tingling toes or feet (OR = 1.47; 95 {\%} CI 1.04–2.07), numbness in toes or feet (OR = 1.83; 95 {\%} CI 1.28–2.62), and erection problems among men (OR = 1.83; 95 {\%} CI 1.11–3.03) as compared to CRC patients without diabetes. No differences in cancer treatment were found between CRC patients with and without diabetes.ConclusionCRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancer patients with diabetes compared to those without.Implications for Cancer SurvivorsUp to 39 {\%} of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes.Keywords: Colorectal cancer, Diabetes, Neuropathic symptoms, Treatment, PROFILES, Eindhoven Cancer Registry",
author = "P.A.J. Vissers and F. Mols and M.S.Y. Thong and F. Pouwer and G. Vreugdenhil and {van de Poll-Franse}, L.V.",
year = "2015",
doi = "10.1007/s11764-015-0429-z",
language = "English",
volume = "9",
pages = "523--531",
journal = "Journal of Cancer Survivorship",
issn = "1932-2259",
publisher = "Springer New York",
number = "3",

}

The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients : Results from the PROFILES registry. / Vissers, P.A.J.; Mols, F.; Thong, M.S.Y.; Pouwer, F.; Vreugdenhil, G.; van de Poll-Franse, L.V.

In: Journal of Cancer Survivorship, Vol. 9, No. 3, 2015, p. 523-531.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients

T2 - Results from the PROFILES registry

AU - Vissers, P.A.J.

AU - Mols, F.

AU - Thong, M.S.Y.

AU - Pouwer, F.

AU - Vreugdenhil, G.

AU - van de Poll-Franse, L.V.

PY - 2015

Y1 - 2015

N2 - PurposeThis study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancer patients with diabetes less often receive chemotherapy.MethodsData from a cross-sectional study among CRC patients (2–11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20).ResultsTwo hundred eighteen CRC patients with diabetes were matched on age and sex to 975 CRC patients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRC patients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95 % confidence interval (CI) 1.00–1.94), tingling toes or feet (OR = 1.47; 95 % CI 1.04–2.07), numbness in toes or feet (OR = 1.83; 95 % CI 1.28–2.62), and erection problems among men (OR = 1.83; 95 % CI 1.11–3.03) as compared to CRC patients without diabetes. No differences in cancer treatment were found between CRC patients with and without diabetes.ConclusionCRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancer patients with diabetes compared to those without.Implications for Cancer SurvivorsUp to 39 % of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes.Keywords: Colorectal cancer, Diabetes, Neuropathic symptoms, Treatment, PROFILES, Eindhoven Cancer Registry

AB - PurposeThis study assessed differences in neuropathic symptoms between colorectal cancer (CRC) patients with and without diabetes. Moreover, we aimed to explore whether neuropathic symptoms could be explained by the receipt of chemotherapy as it was previously shown that cancer patients with diabetes less often receive chemotherapy.MethodsData from a cross-sectional study among CRC patients (2–11 years after diagnosis) was used. Data were collected by the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical data from the population-based Eindhoven Cancer Registry. Diabetes status was self-reported and neuropathic symptoms were measured with the European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy-induced peripheral neuropathy 20 (EORTC QLQ-CIPN20).ResultsTwo hundred eighteen CRC patients with diabetes were matched on age and sex to 975 CRC patients without diabetes. After adjustments for cancer treatment including chemotherapy and other covariates, logistic regression models showed that CRC patients with diabetes experienced more mild to severe neuropathic symptoms, including tingling fingers or hands (odds ratio (OR) = 1.40; 95 % confidence interval (CI) 1.00–1.94), tingling toes or feet (OR = 1.47; 95 % CI 1.04–2.07), numbness in toes or feet (OR = 1.83; 95 % CI 1.28–2.62), and erection problems among men (OR = 1.83; 95 % CI 1.11–3.03) as compared to CRC patients without diabetes. No differences in cancer treatment were found between CRC patients with and without diabetes.ConclusionCRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer treatment, suggesting that diabetes itself rather than treatment with chemotherapy results in more neuropathic symptoms among cancer patients with diabetes compared to those without.Implications for Cancer SurvivorsUp to 39 % of cancer survivors might expect mainly mild, neuropathic symptoms, with more symptoms among patients with co-occurring diabetes.Keywords: Colorectal cancer, Diabetes, Neuropathic symptoms, Treatment, PROFILES, Eindhoven Cancer Registry

UR - http://hdl.handle.net/10411/20625

U2 - 10.1007/s11764-015-0429-z

DO - 10.1007/s11764-015-0429-z

M3 - Article

VL - 9

SP - 523

EP - 531

JO - Journal of Cancer Survivorship

JF - Journal of Cancer Survivorship

SN - 1932-2259

IS - 3

ER -